Indication name: Chemotherapy-induced peripheral
neuropathy (CIPN)
Chemotherapy-induced
peripheral neuropathy (CIPN) – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China)
Adverse effects induced by cancer treatment, 20-100% of patients develop a
condition known as chemotherapy-induced peripheral neuropathy (CIPN). CIPN
occurs when peripheral nerves are damaged, resulting in abnormal sensory
function, and pain or loss of motor control. This condition sometimes leads to
chemotherapy dose decrease or cessation, thereby limiting the efficacy of
cancer treatment. The review here discusses the latest aspects of
chemotherapy-associated peripheral neuropathy.
Epidemiology-
According to Thelansis, the estimated total patient pool of
chemotherapy-induced peripheral neuropathy (CIPN) in 8 MM countries is reported
to be 3.35 MN in 2020, 3.47 MN in 2025, and 3.57 MN by 2030. Overall growth of
the patient pool for CIPN in 8MM countries is majorly due to patient available
to each treatment modalities and newly diagnosed patient pool.
Competitive landscape of Chemotherapy-induced
peripheral neuropathy (CIPN) includes
country specific approved as well as pipeline therapies. Any asset/ product
specific designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs
insights of Chemotherapy-induced peripheral
neuropathy (CIPN) across 8 MM market from center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm
and Unmet needs.
Chemotherapy-induced peripheral neuropathy (CIPN) Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
Read
more: Chemotherapy-induced peripheral neuropathy
(CIPN) – Market outlook, Epidemiology, Market Forecast and Competitive
Landscape Report – 2020 To 2030
S. No Asset Company Stage
1 Calmangafodipir Egetis Therapeutics / PledPharma AB Phase 3
2 TRK-750 Toray Industries, Inc Phase 2
3 Olesoxime (TRO19622) Hoffmann-La Roche Phase 2
4 Calmangafodipir PledPharma AB Phase 1
5 leteprinim potassium (Neotrofin) NeoTherapeutics Phase 2
6 thrombomodulin alfa Asahi Kasei Pharma America Corporation Phase 2
No comments:
Post a Comment